This NDC is on FDA's drug shortage list (posted Jul 26, 2023)
Product Information
RELEXXII ER 36 MG TABLET is a brand product labeled by Vertical Pharmaceuticals, LLC, priced at $11.8612 per EA under NDC 68025009710. Its NADAC has been published 92 times since Nov 20, 2024.
FDA first approved this application on Jun 23, 2022.
The High Outlier badge above means this manufacturer's average price in the methylphenidate hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
36 mg/1
Manufacturer
Vertical Pharmaceuticals, LLCNDC
68025009710
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA216117FDA Approved
6/23/2022
On Market Since
6/23/2022
Pharmacological Classes
Price Statistics
The NADAC for RELEXXII ER 36 MG TABLET has been published 92 times since Nov 20, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.8612 per EA |
|---|---|
| All-time high | $12.0550 (Jan 14, 2026) |
| All-time low | $11.8612 (Aug 19, 2026) |
| 52-week high | $12.0550 |
| 52-week low | $11.8612 |
| Median price | $12.0362 |
| Average price | $12.0176 |
| Largest weekly change | -0.8% (Aug 19, 2026) |
| Weeks tracked | 92 |
| Tracking since | Nov 20, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RELEXXII ER 36 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RELEXXII ER 36 MG TABLET, manufactured by Vertical Pharmaceuticals, LLC, is $11.8612 per EA (NDC 68025009710), effective Aug 19, 2026.
How has the price of RELEXXII ER 36 MG TABLET changed over time?
Over the history we have for it, the NADAC for RELEXXII ER 36 MG TABLET has held within roughly two percent of its current level. It has been tracked across 92 weekly CMS publications since Nov 20, 2024.
What are the highest and lowest recorded NADAC prices for RELEXXII ER 36 MG TABLET?
Since Nov 20, 2024, the NADAC for RELEXXII ER 36 MG TABLET has ranged from a low of $11.8612 (Aug 19, 2026) to a high of $12.0550 (Jan 14, 2026), with a median of $12.0362 per EA.
Are there cheaper alternatives to RELEXXII ER 36 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as RELEXXII ER 36 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures RELEXXII ER 36 MG TABLET?
RELEXXII ER 36 MG TABLET (NDC 68025009710) is labeled by Vertical Pharmaceuticals, LLC, and CMS classifies it as a brand product.
Is RELEXXII ER 36 MG TABLET in shortage?
Yes — NDC 68025009710 is currently listed in FDA's drug shortage database (posted Jul 26, 2023).